217 related articles for article (PubMed ID: 27418969)
1. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Hayward C; Patel HC; Patel K; Di Mario C; Lyon AR; Ahsan SY; Rowland E
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):90-4. PubMed ID: 27418969
[TBL] [Abstract][Full Text] [Related]
2. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
Friberg L
Am Heart J; 2018 Nov; 205():118-127. PubMed ID: 30236980
[TBL] [Abstract][Full Text] [Related]
3. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Freemantle N; Lafuente-Lafuente C; Mitchell S; Eckert L; Reynolds M
Europace; 2011 Mar; 13(3):329-45. PubMed ID: 21227948
[TBL] [Abstract][Full Text] [Related]
4. Trends in outpatient anti-arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997-2016.
Khan I; Patel HC; Nanayakkara S; Raju H; Voskoboinik A; Mariani JA
Intern Med J; 2018 Apr; 48(4):427-432. PubMed ID: 29205742
[TBL] [Abstract][Full Text] [Related]
5. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
[TBL] [Abstract][Full Text] [Related]
6. The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease.
Wang SR; Huang KC; Lin TT; Chuang SL; Yang YY; Wu CK; Lin LY
Int J Cardiol; 2024 Aug; 409():132198. PubMed ID: 38782070
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation.
Ken-Opurum J; Srinivas SS; Park S; Charland S; Revel A; Preblick R
J Comp Eff Res; 2023 Aug; 12(8):e230065. PubMed ID: 37387403
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
[TBL] [Abstract][Full Text] [Related]
10. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
11. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Wu C; Tcherny-Lessenot S; Dai W; Wang Y; Kechemir H; Gandhi S; Lin S; Juhaeri J
Clin Ther; 2018 Mar; 40(3):450-455.e1. PubMed ID: 29500139
[TBL] [Abstract][Full Text] [Related]
13. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
[TBL] [Abstract][Full Text] [Related]
14. Dronedarone: a promising alternative for the management of atrial fibrillation.
Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
[TBL] [Abstract][Full Text] [Related]
15. A value-based budget impact model for dronedarone compared with other rhythm control strategies.
Ken-Opurum J; Srinivas SS; Vadagam P; Faith L; Park S; Charland S; Revel A; Preblick R
J Comp Eff Res; 2023 Apr; 12(4):e220196. PubMed ID: 36916711
[No Abstract] [Full Text] [Related]
16. Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Piccini JP; Kong DF
Europace; 2011 Mar; 13(3):295-6. PubMed ID: 21345924
[No Abstract] [Full Text] [Related]
17. Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Qin D; Leef G; Alam MB; Rattan R; Munir MB; Patel D; Khattak F; Adelstein E; Jain SK; Saba S
J Cardiol; 2016 May; 67(5):471-6. PubMed ID: 26233885
[TBL] [Abstract][Full Text] [Related]
18. Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.
Singh JP; Blomström-Lundqvist C; Turakhia MP; Camm AJ; Fazeli MS; Kreidieh B; Crotty C; Kowey PR
Clin Cardiol; 2023 Jun; 46(6):589-597. PubMed ID: 37025083
[TBL] [Abstract][Full Text] [Related]
19. Dronedarone for atrial fibrillation: a new therapeutic agent.
Patel PD; Bhuriya R; Patel DD; Arora BL; Singh PP; Arora RR
Vasc Health Risk Manag; 2009; 5():635-42. PubMed ID: 19688104
[TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Chiou WR; Huang CC; Lin PL; Chuang JY; Liu LY; Su MI; Liao FC; Chen CY; Kuo JY; Tsai CT; Wu YJ; Lee YH
Am J Cardiovasc Drugs; 2021 Jul; 21(4):459-469. PubMed ID: 33369716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
